Abstract
To the Editor: Psoriatic arthritis affects 20% to 30% of patients with psoriasis; however, little is known about racial and ethnic differences in prevalence.1 Limited knowledge regarding disease manifestations in non-White races is exacerbated by an underrepresentation of non-White participants in clinical trials.2 To determine the extent of underrepresentation, a cross-sectional study was performed assessing differences in patient race and ethnicity in completed phase III clinical trials for biologic agents used to treat psoriatic arthritis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
